ClinicalTrials.gg
RecruitingNCT05608772RCTresleeveUpdated Sep 16, 2025

Conversion to SADI-S, RYGB or OAGB After Failed Sleeve

An interventional study of revision surgery in Weight Loss, Bariatric Surgery Candidate and Comorbidities and Coexisting Conditions, sponsored by General Committee of Teaching Hospitals and Institutes, Egypt. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by General Committee of Teaching Hospitals and Institutes, Egypt · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
234
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Weight Loss with a site in Egypt — 4 open to participants now, 4 under way, none of them phase 3. Weight Loss · Egypt.

Started
2023
with 1 other
No phase
7 of 11
4 open now
Registered
4th of 11
by date
Lead sponsor
4 of 11
General Committee of Teaching Hospitals and Institutes, Egypt

Among the 11 studies in Weight Loss with a site in Egypt, this one is one of 2 that started in 2023, is one of 7 with no phase, and was the 4th registered.

Weight Loss

1,821 studies on the registry are indexed under Weight Loss; 299 are open to participants now.

Browse Weight Loss studies →

Open to participants now

4 of the 11 studies in Weight Loss with a site in Egypt are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 200 Weight Loss studies recruiting now, 74 (37%) set no upper age limit and 109 (55%) stop at 75 or younger; 21 take children under 18; 57 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Weight Loss with a site in Egypt, or all of them as a file.
02

Study summary

Assess what revisional surgery is superior and provides the best weight loss after primary LSG. What is the occurrence of complications and the nutritional laboratory status? And if the resolution and /or improvement of associated medical problems after the weight loss will occur.

Read the detailed description

Laparoscopic sleeve gastrectomy (LSG) gained popularity and has become one of the most performed weight loss procedures worldwide. In the long-term follow-up, the literature states that the incidence of gastroesophageal reflux disease (GERD) accounts for 16%, and weight regains accounting for 70% after LSG. These are the two most common complications which can necessitate further surgical intervention.

The hypotheses are that laparoscopic conversion from LSG to Single anastomosis duodeno-ileal bypass (SADI-S), Roux-en-Y gastric bypass (RYGB), or one anastomosis gastric bypass (OAGB) will provide a new significant weight loss, improvement in obesity-related health problems and provide no nutritional deficiency in all cases.

Since the three types of procedures have other anatomical presentations, whereby these is not well tested next to each other in a blinded, controlled setting for the patient, this study is designed to discover if the procedures are superior to each other or not and what the best outcome is for the patient.

A sample size is calculated and with a medium effect size of 0.5 corresponds to a mean difference in %EBMIL between SADI-S, RYGB, and OAGB of at least 10%. Using a power of 0.8 with an alpha of 0.05 resulted in a sample size of 64 patients per group.

Considering a possible loss of patients to follow-up, an additional 20% increase in sample size was included per group, resulting in a minimum of 78 patients per group.

(Total of 3 groups together of 234 patients).

03

Conditions studied

  • Weight Loss
  • Bariatric Surgery Candidate
  • Comorbidities and Coexisting Conditions
  • Nutrient Deficiency

Browse trials for

Keywords

  • RYGB
  • OAGB
  • SADI-S
  • Sleeve gastrectomy
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergone primary laparoscopic sleeve gastrectomy in the past
  • Weight regain

    • defined as any increase in weight above the nadir as reported by the patient
    • at the time of revisional surgery was around 45 kg/m2
    • weight regain was defined as an increase in BMI after bariatric surgery to exceed 35
  • With or without Gastroesophageal reflux disease (GERD) grade A and B o Patients with grade C or higher GERD, according to the Los Angeles (LA) classification [7] will be excluded from the study

Exclusion criteria

Exclusion Criteria:

  • Didn't follow preoperative consultation
  • Cannot give of sign
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
234 participants (estimated)

Study arms

  • Active comparator
    RYGB procedure arm 1

    After failed sleeve, the patients will get a revisional procedure. The RYGB

    Procedure: revision surgery

  • Active comparator
    OAGB procedure arm 2

    After failed sleeve, the patients will get a revisional procedure. The OAGB

    Procedure: revision surgery

  • Active comparator
    SADI-S procedure arm 3

    After failed sleeve, the patients will get a revisional procedure. The SADI-S

    Procedure: revision surgery

Interventions

  • Procedurerevision surgery

    revision procedure after failed sleeve gastrectomy

06

What researchers measure

Primary outcomes

  1. The number of participants who will have early complications related to surgery

    the incidence of re-operation, bleeding or leakages

    Time frame: 6 weeks

  2. The percentage Excess body weight loss (%EWL)

    the amount of weight loss after revision surgery

    Time frame: 3,6,12,24 months

  3. somscore of food tolerance

    validated food tolerance questions: Food tolerance (FT) was evaluated using a one-page questionnaire divided into 4 sections, 3 of which were used to calculate the score: overall patient satisfaction with eating (score: 1-5); tolerability to certain food types (score: 0-16); and frequency of vomiting/regurgitation (score: 0-6), with a total score between 1 and 27; higher scores indicate better food tolerance

    Time frame: 2,6 weeks and 3,6,12,24 months

Secondary outcomes

  1. Nutritional levels of albuminemia

    the albuminemia level will be tested after surgery (g/dl)

    Time frame: 3,6,12,24 months

  2. Nutritional levels of proteinemia

    the proteinemia level will be tested after surgery (mg/dl)

    Time frame: 3,6,12,24 months

  3. Nutritional levels of anemia

    the anemia level will be tested after surgery (Mcl)

    Time frame: 3,6,12,24 months

  4. Nutritional levels of calcemic

    the calcemic level will be tested after surgery (mg/dl)

    Time frame: 3,6,12,24 months

  5. Incidence of Reflux

    GERD assessment

    Time frame: 3,6,12,24 months

  6. The number of participants who will have late complications related to surgery

    the incidence of re-operations will be collected

    Time frame: 3,6,12,24 months

  7. Short Form 36 Quality of life

    Quality of life assessment will be tested 8 chapters with in total 36 questions and a somscore from 0-100 will be calculated (the higher the somscore the better the quality of life is).

    Time frame: 3,6,12,24 months

  8. VAS/NRS (incidence of pain)

    pain scoring from 0-10 (0 is no pain 10 is most worst pain)

    Time frame: 3,6,12,24 months

  9. Metabolic biomarkers Glucagon-like peptide-1 (GLP1)

    the GLP1 level will be tested after surgery (mg/ml)

    Time frame: 3,6,12,24 months

  10. Metabolic biomarkers Leptin

    the Leptin level will be tested after surgery (mg/ml)

    Time frame: 3,6,12,24 months

  11. Metabolic biomarkers Peptide YY ( PYY)

    the PYY level will be tested after surgery (pg/ml)

    Time frame: 3,6,12,24 months

  12. Metabolic biomarkers Ghrelin

    the Ghrelin level will be tested after surgery (mg/ml)

    Time frame: 3,6,12,24 months

  13. Metabolic biomarkers Insulin

    the Insulin level will be tested after surgery (million units/ml)

    Time frame: 3,6,12,24 months

Other outcomes

  1. The number of participants who will have late complications related to surgery

    the incidence of re-operations or complications will be collected

    Time frame: 60 months

  2. The number of participants whereby revision surgery necessary after the RCT

    the incidence of re-operations or other procedure will be collected

    Time frame: 60 months

  3. The percentage Excess body weight loss (%EWL)

    the amount of weight loss after revision surgery

    Time frame: 60 months

  4. Incidence of Reflux

    GERD classification

    Time frame: 60 months

  5. Nutritional levels of albuminemia

    the albuminemia level will be tested after surgery (g/dl)

    Time frame: 60 months

  6. Nutritional levels of proteinemia

    the proteinemia level will be tested after surgery (mg/dl)

    Time frame: 60 months

  7. Nutritional levels of anemia

    the anemia level will be tested after surgery (Mcl)

    Time frame: 60 months

  8. Nutritional levels of calcemic

    the calcemic level will be tested after surgery (mg/dl)

    Time frame: 60 months

  9. Somscore of food tolerance

    validated food tolerance questions: Food tolerance (FT) was evaluated using a one-page questionnaire divided into 4 sections, 3 of which were used to calculate the score: overall patient satisfaction with eating (score: 1-5); tolerability to certain food types (score: 0-16); and frequency of vomiting/regurgitation (score: 0-6), with a total score between 1 and 27; higher scores indicate better food tolerance

    Time frame: 60 months

  10. Short Form 36 Quality of life

    Quality of life assessment will be tested 8 chapters with in total 36 questions and a somscore from 0-100 will be calculated (the higher the somscore the better the quality of life is).

    Time frame: 60 months

  11. VAS/NRS (incidence of pain)

    pain scoring from 0-10 (0 is no pain 10 is most worst pain)

    Time frame: 60 months

  12. Metabolic biomarkers Glucagon-like peptide-1 (GLP1)

    the GLP1 level will be tested after surgery (mg/ml)

    Time frame: 60 months

  13. Metabolic biomarkers Leptin

    the Leptin level will be tested after surgery (mg/ml)

    Time frame: 60 months

  14. Metabolic biomarkers Peptide YY ( PYY)

    the PYY level will be tested after surgery (pg/ml)

    Time frame: 60 months

  15. Metabolic biomarkers Ghrelin

    the Ghrelin level will be tested after surgery (mg/ml)

    Time frame: 60 months

  16. Metabolic biomarkers Insulin

    the Insulin level will be tested after surgery (million units/ml)

    Time frame: 60 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Guan B, Chong TH, Peng J, Chen Y, Wang C, Yang J. Mid-long-term Revisional Surgery After Sleeve Gastrectomy: a Systematic Review and Meta-analysis. Obes Surg. 2019 Jun;29(6):1965-1975. doi: 10.1007/s11695-019-03842-3. PubMed 30903425 ↗
  • Lazzati A, Bechet S, Jouma S, Paolino L, Jung C. Revision surgery after sleeve gastrectomy: a nationwide study with 10 years of follow-up. Surg Obes Relat Dis. 2020 Oct;16(10):1497-1504. doi: 10.1016/j.soard.2020.05.021. Epub 2020 May 29. PubMed 32636173 ↗
  • Clapp B, Wynn M, Martyn C, Foster C, O'Dell M, Tyroch A. Long term (7 or more years) outcomes of the sleeve gastrectomy: a meta-analysis. Surg Obes Relat Dis. 2018 Jun;14(6):741-747. doi: 10.1016/j.soard.2018.02.027. Epub 2018 Mar 6. PubMed 29625744 ↗
  • Parmar CD, Gan J, Stier C, Dong Z, Chiappetta S, El-Kadre L, Bashah MM, Wang C, Sakran N. One Anastomosis/Mini Gastric Bypass (OAGB-MGB) as revisional bariatric surgery after failed primary adjustable gastric band (LAGB) and sleeve gastrectomy (SG): A systematic review of 1075 patients. Int J Surg. 2020 Sep;81:32-38. doi: 10.1016/j.ijsu.2020.07.007. Epub 2020 Jul 29. PubMed 32738545 ↗
  • Chiappetta S, Stier C, Scheffel O, Squillante S, Weiner RA. Mini/One Anastomosis Gastric Bypass Versus Roux-en-Y Gastric Bypass as a Second Step Procedure After Sleeve Gastrectomy-a Retrospective Cohort Study. Obes Surg. 2019 Mar;29(3):819-827. doi: 10.1007/s11695-018-03629-y. PubMed 30542828 ↗
  • Angrisani L, Santonicola A, Iovino P, Ramos A, Shikora S, Kow L. Bariatric Surgery Survey 2018: Similarities and Disparities Among the 5 IFSO Chapters. Obes Surg. 2021 May;31(5):1937-1948. doi: 10.1007/s11695-020-05207-7. Epub 2021 Jan 12. PubMed 33432483 ↗
  • Sami S, Ragunath K. The Los Angeles Classification of Gastroesophageal Reflux Disease. Video Journal and Encyclopedia of GI Endoscopy. 2013;1:103-4.

Individual participant data

Plan to share: Yes — FAIR data of this study can be requested. All will be saved in the Castor Electronic data capture system.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: After 2 and 5 years and after full analysis and publication the data will be available and stored for minimal 10 years.

Access criteria: Email the Principal investigator. Whereby access to an annonymous database site will be created.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2028, 60 months after the start.

Of 671 non-industry interventional studies with no phase under Weight Loss, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 60 months is above that.

Counting every sponsor, half of 730 studies reached it within 24 months; a quarter within 11 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2022
First posted
Nov 8, 2022
StartActual
Mar 15, 2023
Primary completionEst.
Mar 15, 2028
CompletionEst.
Apr 15, 2028
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05608772
Lead sponsor
General Committee of Teaching Hospitals and Institutes, Egypt
Responsible party
Mohamed Hany Ashour (ass professor, General Committee of Teaching Hospitals and Institutes, Egypt) — Principal investigator
First posted
Nov 8, 2022
Start date
Mar 15, 2023
Primary completion
Mar 15, 2028 (estimated)
Completion
Apr 15, 2028 (estimated)
Last update
Sep 16, 2025

Study contacts

Bart Torensma, PHD
Contact
bart@torensmaresearch.nl
+31641389070
Mohamed Ashour, MD
Contact
mohamed.ashour@alexu.edu.eg
+201002600970
Mohamed Ashour, MD
principal investigator · University of Alexandria

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion